Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Biophytis ( (BPTSY) ) just unveiled an announcement.
On May 15, 2025, Biophytis SA announced its active participation in the 32nd European Congress on Obesity, held from May 11 to 14 in Malaga, Spain. During the event, Biophytis presented promising clinical development data from its OBA program with the drug candidate BIO101, which targets muscle loss in obese patients treated with GLP-1 receptor agonists. The presentation highlighted the potential benefits of BIO101 in preserving muscle function and reducing fat mass, supporting the advancement of a phase 2 clinical trial. This participation underscores Biophytis’ commitment to advancing therapeutic options for obesity-related muscle loss, potentially enhancing its industry positioning.
The most recent analyst rating on (BPTSY) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Biophytis stock, see the BPTSY Stock Forecast page.
Spark’s Take on BPTSY Stock
According to Spark, TipRanks’ AI Analyst, BPTSY is a Underperform.
Biophytis faces significant financial challenges, with ongoing losses and negative equity posing major risks. While there is some short-term technical strength, the long-term technical indicators and valuation metrics highlight weaknesses. The lack of substantial earnings call information increases uncertainty, contributing to a low overall score.
To see Spark’s full report on BPTSY stock, click here.
More about Biophytis
Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases. Its lead drug candidate, BIO101 (20-hydroxyecdysone), is being developed for muscular diseases and metabolic disorders. The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. Biophytis is listed on Euronext Growth Paris and the OTC market.
Average Trading Volume: 13
Technical Sentiment Signal: Sell
Current Market Cap: $3.63M
See more insights into BPTSY stock on TipRanks’ Stock Analysis page.